HEM Pharma signs single‑sale supply contract with Access Business Group for new probiotic product (KRW 4.6 bn)
HEM Pharma entered a KRW 4.6 bn supply agreement with Access Business Group for a new probiotic product.
How this call is verified
The ▲ Bullish call is auto-verified against the actual KOSPI price in ~8h.
Bar: KOSPI ±0.9% within 24h · every verdict lands on the public ledger
AI comment — why bullish
The KRW 4.6 bn probiotic supply contract is likely to lift HEM Pharma’s earnings in the next reporting period. The agreement represents 35.48% of the company’s most recent revenue, indicating a material contribution to top‑line growth. Because the contract covers both domestic and overseas markets, it diversifies the company’s sales footprint. However, the filing does not disclose pricing terms or cost structure, leaving the exact margin impact uncertain. If the anticipated volume materializes, the deal could improve profitability; if not, the revenue boost may be limited.
Market data
HEM파마 · 376270 · KOSDAQ →Previous-close data, updated T+1 · Source: Financial Services Commission of Korea via data.go.kr
Key takeaway
"HEM Pharma signs single‑sale supply contract with Access Business Group for new probiotic product (KRW 4.6 bn)" — BullBear's AI rates this story as a bullish (positive) signal for markets, with a market-impact score of 72 out of 100. That score reflects how strongly the story is likely to move Bitcoin, US equities, the dollar, and gold, and near-duplicate coverage of the same event is clustered so only the representative article is scored. Reported by 금융감독원 전자공시(DART) on September 04, 2026. The call is verified against the actual 24-hour price move on BullBear's public conviction ledger.
Catch the next bull catalyst
Telegram alerts when our AI scores a story 80+/100 impact (~1-3 per day, no spam). Verified 30d hit rate 40.2%.